Products - Headaches | Topic | NICE

Showing 23 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter

Atogepant for preventing migraine (TA973)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Rimegepant for treating migraine (TA919)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Suspected neurological conditions: recognition and referral (NG127)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
1 May 2019
Rimegepant for preventing migraine (TA906)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2023
Eptinezumab for preventing migraine (TA871)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 March 2023
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (IPG740)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 October 2022
Fremanezumab for preventing migraine (TA764)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Headaches in over 12s: diagnosis and management (CG150)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
17 December 2021
Published:
19 September 2012
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)
Product type:
Guidance
Programme:
NICE guideline
Published:
7 April 2021
Erenumab for preventing migraine (TA682)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Galcanezumab for preventing migraine (TA659)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
gammaCore for cluster headache (MTG46)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
3 December 2019
Tocilizumab for treating giant cell arteritis (TA518)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 April 2018
Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 March 2016
Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache (IPG527)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 June 2015
Transcranial magnetic stimulation for treating and preventing migraine (IPG477)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 January 2014
Occipital nerve stimulation for intractable chronic migraine (IPG452)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 April 2013
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Deep brain stimulation for intractable trigeminal autonomic cephalalgias (IPG381)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 March 2011
Percutaneous closure of patent foramen ovale for recurrent migraine (IPG370)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
15 December 2010
Migraine prophylaxis: flunarizine (ESUOM33)
Product type:
Advice
Programme:
Evidence summary
Published:
30 September 2014
Suspected neurological conditions: recognition and referral (QS198)
Product type:
Quality standard
Published:
8 January 2021
Headaches in over 12s (QS42)
Product type:
Quality standard
Published:
28 August 2013